Quarterly ResultAug 3, 2026, 07:02 AM
Supernus Q2 Net Loss $(58.37)M; Revenue $219.06M
AI Summary
Supernus Pharmaceuticals reported a net loss of $(58.37) million for Q2 2026, a significant decline from net earnings of $22.50 million in Q2 2025, primarily due to a $54.92 million intangible asset impairment charge. Despite the loss, total revenues grew by 32.4% to $219.06 million, driven by new collaboration revenue from ZURZUVAE and increased net product sales. Basic EPS for the quarter was $(1.01).
Key Highlights
- Q2 2026 net loss was $(58.37) million, compared to net earnings of $22.50 million in Q2 2025.
- Total revenues for Q2 2026 increased to $219.06 million from $165.45 million in Q2 2025.
- Net product sales for Q2 2026 were $165.71 million, up from $158.00 million in Q2 2025.
- Collaboration revenue from ZURZUVAE was $35.35 million in Q2 2026.
- The company incurred $54.92 million in intangible asset impairment charges in Q2 2026.
- Basic EPS for Q2 2026 was $(1.01), down from $0.40 in Q2 2025.
- Cash and cash equivalents stood at $179.95 million as of June 30, 2026.
- Shionogi collaboration generated $20.0 million licensing revenue in H1 2026.
Price Impact
More from SUPN